Circulating PCSK9 Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors Running title: Leander et al.; PCSK9 and incident cardiovascular events
نویسندگان
چکیده
Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Stockholm, Sweden; Cardiovascular Genetics and Genomics Group, Cardiovascular Medicine Unit, Dept of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Pharmatherapeutics Clinical Research, Pfizer Worldwide R&D, Sollentuna, Sweden; Research Statistics, Pfizer Worldwide R&D, Cambridge, MA; Dept of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN; Cardiology Unit, Karolinska University Hospital, Stockholm, Sweden *contributed equally
منابع مشابه
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies.
BACKGROUND Previous studies have not found a consistent association between circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of cardiovascular events. The aim of this meta-analysis was to evaluate this association in prospective studies.Methods and Results:A systematic search of prospective studies published through October 2016 was carried out in order to identify...
متن کاملLipid Lowering Therapy and Circulating PCSK9 Concentration
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events. As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events. However, despite intensive statin therapy, a sizable proportion of st...
متن کاملPlasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events.
AIMS Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted protein that enhances degradation of the LDL receptor. While agents that inhibit PCSK9 markedly reduce atherogenic lipoproteins and show great promise for event reduction, it is unknown whether plasma PCSK9 levels predict incident cardiovascular events. METHODS AND RESULTS In a nested case-control evaluation conducted in...
متن کاملHigh circulating proprotein convertase subtilisin/Kexin type 9 concentration associates with cardiovascular risk
Whether the baseline circulating proprotein convertase subtilisin/Kexin type 9 (PCSK9) concentration associates with cardiovascular risk remains uncertain. This study aimed to investigate the predictive value of circulating PCSK9 in cardiovascular risk prediction.Relevant studies were searched through the MEDLINE, EMBASE, and Cochrane Library databases. The relative risk (RR) and 95% confidence...
متن کاملAssociation of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
OBJECTIVE Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of low-density lipoprotein metabolism. This study was conducted to evaluate the relationship between serum PCSK9 concentrations and measures of vascular health, subclinical atherosclerosis, and adverse cardiovascular events. The relationship between traditional risk factors and PCSK9 concen...
متن کامل